Announcements Trials

Browse Landscape

Phase

Phase 2 10 Phase 1/2 3 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12 Myeloid 4 Lymphoid 4 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 77 Radiotherapy 73 Prednisone 66 Leuprolide 51 Goserelin 49 Gemcitabine 49 Cisplatin 48 bicalutamide 46 enzalutamide 43 Androgen Antagonists 36 pembrolizumab 32 Abiraterone Acetate 31 Mitomycin 29 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28 Magnetic Resonance Spectroscopy 28 Carboplatin 27 Flutamide 25 Nivolumab 24 Triptorelin Pamoate 23 Sunitinib 23 apalutamide 22 Radiation 22 Doxorubicin 20 darolutamide 19 abiraterone 18 Gonadotropin-Releasing Hormone 18 cabozantinib 17 atezolizumab 16 Specimen Handling 16 Radiosurgery 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Dasatinib × Genitourinary × Clear all

NCT00744497 2016-10-17

READY

Bristol-Myers Squibb

Phase 3 Completed

1,930 enrolled 23 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡